Vanda Pharmaceuticals Inc
Closed
5.32 1.53
Overview
Share price change
24h
Min
5.13
Max
5.38
Income | 93M -49M |
|---|---|
Sales | -5.5M 52M |
EPS | -0.46 |
Profit margin | -93.907 |
Employees | 533 |
EBITDA | -10M -45M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +256.98% upside |
Next Earnings | 5 sie 2026 |
|---|
Market Cap | -140M 315M |
|---|---|
Previous open | 3.79 |
Previous close | 5.32 |
Vanda Pharmaceuticals Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Vanda Pharmaceuticals Inc Forecast
Price Target
By TipRanks
256.98% upside
12 Months Forecast
Average 18.67 USD 256.98%
High 21 USD
Low 17 USD
Based on 3 Wall Street analysts offering 12 month price targets forVanda Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
